The short version of Regulatory status fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-15 and is reviewed periodically as new material appears.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Measurement of the electrical activity of the heart (ECG) Measurement of blood pressure, heart rate, and body temperature Blood sampling Urine sampling Weight and height measurement Drug abuse testing Pregnancy testing It has been observed that participants in clinical trials are disproportionately white. Often, minorities are not informed about clinical trials. One recent systematic review of the literature found that race/ethnicity as well as sex were not well-represented nor at times even tracked as participants in a large number of clinical trials of hearing loss management in adults. This may reduce the validity of findings in respect of non-white patients by not adequately representing the larger populations.
=== Opioid agonist === β-Endorphin is an agonist of the opioid receptors; it preferentially binds to the μ-opioid receptor. Evidence suggests that it serves as a primary endogenous ligand for the μ-opioid receptor, the same receptor to which the chemicals extracted from opium, such as morphine, derive their analgesic properties. β-Endorphin has the highest binding affinity of any endogenous opioid for the μ-opioid receptor. Opioid receptors are a class of G-protein coupled receptors, such that when β-endorphin or another opioid binds, a signaling cascade is induced in the cell. Acetylation of the N-terminus of β-endorphin, however, inactivates the neuropeptide, preventing it from binding to its receptor. The opioid receptors are distributed throughout the central nervous system and within the peripheral tissue of neural and non-neural origin. They are also located in high concentrations in the periaqueductal gray, locus coeruleus, and the rostral ventromedial medulla. In addition to the full-length peptide, brain and pituitary tissue also contain shorter β-endorphin fragments such as β-endorphin(1–27), which can act as a competitive antagonist at μ-opioid receptors and attenuate the analgesic effects of β-endorphin(1–31) in experimental models. Voltage-dependent calcium channels (VDCCs) are important membrane proteins that mediate the depolarization of neurons, and play a major role in promoting the release of neurotransmitters. When endorphin molecules bind to opioid receptors, G proteins activate and dissociate into their constituent Gα and Gβγ sub-units.
=== IRTA === The International Refrigerated Transportation Association (IRTA) was established in 1994 to meet a growing demand in the transportation industry for chilled and frozen food products. IRTA was led by a core group of international companies, including companies which specialize in transportation categories across the cold chain. IRTA members were companies primarily involved in ports, trucking, warehousing, logistics, marine shipping, railroads, and airplane transportation, or any combination of these industries.
Sources: en.wikipedia.org
=== Pyrosequencing === Similar to its use in direct Sanger sequencing, with pyrosequencing COLD-PCR was shown to be capable of detecting mutations that had a prevalence 0.5–1% from the samples used. COLD-PCR was used to detect p53 and KRAS mutations by pyrosequencing, and was shown to outperform conventional PCR in both cases.
==== Agriculture ==== The most substantial human use of water is for agriculture, including irrigated agriculture, which accounts for as much as 80 to 90 percent of total human water consumption. In the United States, 42% of freshwater withdrawn for use is for irrigation, but the vast majority of water "consumed" (used and not returned to the environment) goes to agriculture. Access to fresh water is often taken for granted, especially in developed countries that have built sophisticated water systems for collecting, purifying, and delivering water, and removing wastewater. But growing economic, demographic, and climatic pressures are increasing concerns about water issues, leading to increasing competition for fixed water resources, giving rise to the concept of peak water. As populations and economies continue to grow, consumption of water-thirsty meat expands, and new demands rise for biofuels or new water-intensive industries, new water challenges are likely. An assessment of water management in agriculture was conducted in 2007 by the International Water Management Institute in Sri Lanka to see if the world had sufficient water to provide food for its growing population. It assessed the current availability of water for agriculture on a global scale and mapped out locations suffering from water scarcity. It found that a fifth of the world's people, more than 1.2 billion, live in areas of physical water scarcity, where there is not enough water to meet all demands.
== Uses == NMNH can act as a potent NAD+ enhancer, potentially leading to a new generation of highly efficient NAD+-boosting molecules that could overcome the limitations of current NAD+ enhancers. [18] NMNH protects tubular epithelial cells against hypoxia/reoxygenation injury by enhancing repair.
transfer RNA (tRNA) Formerly referred to as soluble RNA (sRNA). A special class of RNA molecule, typically 76 to 90 nucleotides in length, that serves as a physical adapter allowing mRNA transcripts to be translated into sequences of amino acids during protein synthesis. Each tRNA contains a specific anticodon triplet corresponding to an amino acid that is covalently attached to the tRNA's opposite end; as translation proceeds, tRNAs are recruited to the ribosome, where each mRNA codon is paired with a tRNA containing the complementary anticodon. Depending on the organism, cells may employ as many as 41 distinct tRNAs with unique anticodons; because of codon degeneracy within the genetic code, several tRNAs containing different anticodons carry the same amino acid.
Sources: en.wikipedia.org
Statin-associated autoimmune myopathy (SAAM), also known as anti-HMGCR myopathy, is a very rare form of muscle damage caused by the immune system in people who take statin medications. However, there are cases of SAAM in patients who have not taken statin medication, and this can be explained by the exposure to natural sources of statin such as red yeast rice, which is statin rich. This theory is supported by the higher prevalence of statin-naive SAAM patients in Asian cohorts, who have statin-rich diets. The exact cause is unclear. A combination of consistent findings on physical examination, the presence of anti HMG-CoA reductase antibodies in a person with myopathy, evidence of muscle breakdown, and muscle biopsy diagnose SAAM. Treatment involves stopping the associated statin medication and taking medication to suppress the immune system. SAAM is estimated to occur in 2-3 people out of every 100,000 statin-treated individuals. It appears to be more common in people over the age of 50.
Type I, slow-twitch, slow oxidative, or red muscle is dense with capillaries and is rich in mitochondria and myoglobin, giving the muscle tissue its characteristic red color. It can carry more oxygen and sustain aerobic activity. Type II, fast-twitch muscle, has three major kinds that are, in order of increasing contractile speed: Type IIa, which, like a slow muscle, is aerobic, rich in mitochondria and capillaries and appears red when deoxygenated. Type IIx (also known as type IId), which is less dense in mitochondria and myoglobin. This is the fastest muscle type in humans. It can contract more quickly and with a greater amount of force than oxidative muscle, but can sustain only short, anaerobic bursts of activity before muscle contraction becomes painful (often incorrectly attributed to a build-up of lactic acid). N.B. in some books and articles this muscle in humans was, confusingly, called type IIB. Type IIb, which is anaerobic, glycolytic, "white" muscle that is even less dense in mitochondria and myoglobin. In small animals like rodents, this is the major fast muscle type, explaining the pale color of their flesh. In laboratory house mice, an intronic single nucleotide polymorphism in the Myosin heavy polypeptide 4 gene causes a great reduction in the amount of Type IIb muscle, yielding the "Mini-Muscle" phenotype, which was discovered based on its greatly reduced (~50%) hind-limb muscle mass. The density of mammalian skeletal muscle tissue is about 1.06 kg/liter. This can be contrasted with the density of adipose tissue (fat), which is 0.9196 kg/liter.
Stimulants improve focus and alertness. Low (therapeutic) doses of dopaminergic stimulants (e.g., reuptake inhibitors and releasing agents) also promote mental and athletic performance, as cognitive enhancers and ergogenic aids respectively, by improving muscle strength and endurance while decreasing reaction time and fatigue. Stimulants are commonly used in lengthy exercises that require short bursts (e.g., tennis, team sports, etc.). Stimulants work by increasing catecholamine levels and agonistic activity at the adrenergic receptors. Examples of stimulants include caffeine, ephedrine, methylphenidate and amphetamine. Potential side effects include hypertension, insomnia, headaches, weight loss, arrhythmia, tremors, anxiety, addiction, and strokes. Some stimulants are allowed in competitive sports and are widely accessible, though may also be monitored by the World Anti-Doping Agency (WADA), such as caffeine. Others are banned as per the WADA (e.g., cocaine, amphetamines, ephedrine, etc.).
Additionally, in January 1978, the band appeared as themselves in two episodes of the ABC sitcom What's Happening!!, performing "Echoes of Love," "Little Darlin' (I Need You)", "Black Water", "Takin' It to the Streets", and "Take Me in Your Arms". Performances were done live (versus lip synching to a pre-recorded track), with some overdubs added in post production, notably during Baxter's solo on "Take Me in Your Arms (Rock Me a Little While)," which was lifted from the album version. After almost a decade on the road, and with seven albums to their credit, the Doobies' profile was substantially elevated by the success of their next album, 1978's Minute by Minute. It spent five weeks atop the charts and dominated several radio formats for the better part of two years. McDonald's song "What a Fool Believes", written with Kenny Loggins, was the band's second No. 1 single and earned the songwriting duo (along with producer Ted Templeman) a Grammy Award for Record of the Year. The album won a Grammy for Pop Vocal Performance by a Group and was nominated for Album of the Year. Both "What a Fool Believes" and the title track were nominated for Song of the Year, with "What a Fool Believes" winning the award. Among the other memorable songs on the album are "Here to Love You", "Dependin' On You" (co-written by McDonald and Simmons), "Steamer Lane Breakdown" (a Simmons bluegrass instrumental) and McDonald's "How Do the Fools Survive?" (co-written by Carole Bayer Sager). Nicolette Larson and departed former bandleader Johnston contributed guest vocals on the album.
=== Dogs === Paracetamol has been reported to be as effective as aspirin in the treatment of musculoskeletal pain in dogs. Paracetamol is considered a weak analgesic and is usually combined with codeine, although the efficacy of this formulation has not been evaluated. The main effect of toxicity in dogs is liver damage, and GI ulceration has been reported. Acetylcysteine treatment is efficacious in dogs when administered within two hours of paracetamol ingestion.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.